Forest to pay $313 million to settle US criminal, civil charges relating to Levothroid and Celexa
This article was originally published in Scrip
Executive Summary
Forest Laboratories has agreed to pay more than $313 million to settle criminal and civil charges that it distributed an unapproved hypothyroidism drug, obstructed a US FDA regulatory inspection related to that drug, and marketed Celexa (citalopram) and Lexapro (escitalopram) off-label for use in children, the US Department of Justice (DoJ) said.